If you have been diagnosed with Interstitial Cystitis/ Bladder Pain Syndrome (IC/BPS) you may be eligible to participate in a new clinical research study to evaluate the safety and efficacy of an investigational drug made out of natural egg yolk (LP-08). Lipella Pharmaceuticals, Inc. is conducting the study at Beaumont Hospital in Royal Oak, MI.
LP-08, a liposome product, has been studied in a previous clinical research study in the United States. This study includes an “open label extension.” This means that all patients that receive the placebo will be offered the investigational drug according to the study protocol.
The study is seeking 36 men and women age 18 or over. You must have had IC/BPS for a minimum of six months and have been diagnosed by a health care provider. You must be available to attend seven required clinic visits over approximately 12 weeks, including cystoscopies. If you choose to enter the “open label extension” your participation would extend another 12 weeks. Compensation for time/travel is available.
Interested in learning more? Please call 248-551-3355.
Dr. Michael Chancellor, the Director of Neurourology at William Beaumont Hospital, developed LP-08, the drug being tested. Dr. Chancellor will not be involved with conducting the study at William Beaumont Hospital but will benefit financially if the drug is approved for use by the Food and Drug Administration (FDA).